The IGROV-1 cell line is well-established as a model for drug-resistant ovarian carcinoma. IGROV-1 cells lack hormone receptors and exhibit low to moderate sensitivity to several common chemotherapeutic agents, while remaining sensitive to cisplatin (1). IGROV-1 cells harbor a paracentric inversion of chromosome 3 and a translocation between chromosomes 2 and 5 (1). The IGROV-1 cell line exhibits hypermutation and has an overall mutation profile similar to endometrioid carcinoma (2). IGROV-1 cells appear in culture as confluent monolayers and are highly tumorigenic in vivo, forming solid tumors within 15 days in nude mice (1). IGROV-1 cells are characterized by expression of vitronectin and αvα3 integrin, essential for the observed migratory behavior of these cells toward ECM proteins (3), and express the cancer-associated target MDM2 (4). Source: IGROV-1 cells were established from a stage III ovarian solid primary tumor of a 47-year-old female patient (1). Research Category: Cancer ，官网链接：https://www.sigmaaldrich.cn/product/mm/scc203 默克 科研、开发、生产。 作为生命科学行业的全球领先供应商，我们致力于为科研、生物技术开发和生产，以及制药药物疗法开发和生产提供各类解决方案和服务。

非质量问题不退不换